Abstract:Abstract Disclosure: E.B. Geer: Consulting Fee; Self; Amryt. Research Investigator; Self; Ionis, Amryt. W. Huang: Consulting Fee; Self; Amryt. Speaker; Self; Amryt. M.B. Gordon: Consulting Fee; Self; Recordati, Novo Nordisk. Research Investigator; Self; Amryt, Crinetics, Recordati, Novo Nordisk. K.C. Yuen: Consulting Fee; Self; Novo Nordisk, Ipsen, Amryt, Crinetics, Recordati, Xeris. Speaker; Self; Recordati. S.E. Lubitz: None. R. Salvatori: Consulting Fee; Self; Novo Nordisk, Camurus, Recordati, Ipsen. M. Fleseriu: Consulting Fee; Self; Amryt, Camurus, Debiopharm, Ipsen, Recordati, Pfizer, Inc. Research Investigator; Self; Amryt, Crinetics, Ionis. A.G. Ioachimescu: Consulting Fee; Self; Amryt, Recordati, Camurus. E.A. Christofides: Advisory Board Member; Self; Amryt. Speaker; Self; Amryt. J. Sisco: None. S.D. Mathias: Employee; Self; Health Outcomes Solutions. Other; Self; Amryt. J.A. Crompton: Employee; Self; Amryt. M.E. Molitch: Consulting Fee; Self; Amryt, Takeda, Sention, Janssen Research & Development Company. BACKGROUND: The Management of Acromegaly (MACRO) registry is a prospective, observational cohort study of patients with active acromegaly on medical therapy or eligible for medical therapy that includes paired data from patients and their physicians allowing for comparison of symptom-related data. METHODS: Patients and physicians completed questionnaires at enrollment and then every 3 months for up to 3 years. Information collected included demographic, disease activity, and treatment information, including ratings of symptom and biochemical control, and patient-reported outcomes (PROs) (AcroQOL, Acro-TSQ, and WPAI). Descriptive, concordance and correlation statistics were calculated. RESULTS: Data from 199 patients were available (54% female; mean age = 52; mean time since diagnosis = 10 years). IGF-I data was available in 191/199 (96%) patients of which 147/191 (77%) patients were biochemically controlled (defined as a baseline IGF-I level ≤ 1x ULN). Symptoms in biochemically controlled patients at enrollment were as follows: joint pain (54%), fatigue (52%), memory problems (42%), sleep apnea (39%), swelling (31%), headaches (25%), sweating (22%), and visual changes (20%). In the biochemically controlled group, 107/147 (73%) patients and 106/147 (72%) physicians reported symptoms as well-controlled. Conversely, concordance within individual patients between their physician’s and their own rating of symptom control was low (kappa = 0.272; p<0.001). Memory problems, fatigue, and joint pain were the most frequent symptoms reported at baseline by biochemically controlled patients that were not reported by their matched physician (33, 25 and 18% of patients, respectively). In the 45 biochemically controlled patients that rated any of their symptoms as severe, physicians who also reported the symptom provided the same rating of severity in only 5 (11%) cases. In the remaining cases rated as severe by patients, 26 (58%) and 14 (31%) were rated by their physician as mild or moderate. Well-controlled symptoms as reported by patients were associated with significantly higher (better) AcroQOL scores across all scales and 5 of the 6 Acro-TSQ domains (p < 0.001 except injection site interference) and less impairment on 3 of 4 WPAI scales (p < 0.001 except absenteeism). CONCLUSIONS: Symptoms persist in acromegaly patients despite achieving biochemical control. Adequate symptom control and physician-patient agreement on the extent of symptom control continues to be underrecognized and constitutes an unmet need in acromegaly patients despite its association with better patient-reported outcomes. Presentation: Saturday, June 17, 2023

Facial Phenotype Changes and Its Impact in Quality of Life of Acromegaly Patients

Sleep quality in acromegaly and changes after transsphenoidal surgery: a prospective longitudinal study.

The effect of octreotide treatment on somatic and psychological symptoms of acromegaly

SAT622 Matched Physician- and Patient-reported Responses of Acromegaly Symptom Control: Comparisons from the Macro Registry

Preferences for different treatment options among people living with acromegaly in the US

Cutaneous findings in patients with acromegaly and its relationship with concomitant endocrinopathies

Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study

Impact of exercise on quality of life and body-self perception of patients with acromegaly

Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

Dynamic changes in the distribution of facial and abdominal adipose tissue correlated with surgical treatment in acromegaly

THU065 Evaluation Of Sarcopenia And Bone Health In Patients With Acromegaly

Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management

Efficacy and Predictors of Short-Term First-Generation Somatostatin Analog Presurgical Treatment in Acromegaly: A Hospital-Based Study of 237 Cases.

Gastrointestinal symptoms in acromegaly: A case control study

The comprehensive impact on human body induced by resolution of growth hormone excess.

An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies

Evaluation of the relation between subclinical systolic dysfunction defined by four-dimensional speckle-tracking echocardiography and growth differentiation factor-15 levels in patients with acromegaly

Integration of big data analytics in the investigation of the relationship between acromegaly and cancer

Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines

Quantification of Cephalometric Changes in Gonial Angle Morphology Following Facial Feminization Surgery

The Negative Impacts of Acromegaly on Bone Microstructure Not Fully Reversible